Table 1 Clinical trials testing nivolumab in patients with breast cancer
Disease setting | Phase | Clinical trial reference number | Cancer type | Estimated Enrollment | Primary Endpoint | Regimens | Control arm |
|---|---|---|---|---|---|---|---|
Metastatic | II | NCT02892734 | HER2- | 29 | PFS | Nivolumab + ipilimumab | None |
Metastatic | I | NCT02309177 | HER2- | 20 | MTD | Nivolumab + nab-paclitaxel | None |
Metastatic | II | NCT02499367 | TNBC | 84 | PFS | Nivolumab + doxorubicin/cyclophosphamide/cisplatin/radiation | Active Comparator |
Metastatic | I | NCT02453620 | HER2- | 45 | Safety | Nivolumab + entinostat + ipilimumab | None |
Metastatic | I/II | NCT01928394 | TNBC | 58 | ORR | Nivolumab ± ipilimumab | None |
Metastatic | I | NCT02834247 | TNBC | 36 | MTD/ORR | Nivolumab ± TAK659 | None |